Norwegian cancer drug in COVID 19-programme
British health authorities are testing six medicines against the coronavirus and bemcentinib from the Norwegian biotech BerGenBio is the first treatment to be tested.
Bemcentinib is an AXL inhibitor that our member BerGenBio has developed to treat cancer, by boosting the patient’s immune system. Now, bemcentinib will be evaluated by the British government as a treatment option for COVID-19 patients.
On Tuesday, the British government launched the ACCORD programme (Accelerating COVID-19 Research & Development platform). It is an accelerated research and development programme for the treatment of COVID-19.
So far, no medicine has been found to treat COVID-19, but the work group behind ACCORD has selected six promising candidates, of which the drug bemcentinib from BerGenBio is the first to be trialled.
The study will include 120 patients, of which 60 are COVID-19 patients currently in hospital and the other 60 are a control group who receive standard treatment. The first data from the clinical testing may be available already in the next few months. If the results are positive, the clinical trial will continue to a larger second stage (phase 3).
The study is financed by the Department of Health and Social Care and UK Research and Innovation.
Bemcentinib is already in clinical trials as a cancer treatment and early testing has shown that the treatment has antiviral effects.
Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We are delighted to be part of this initiative which is a ground-breaking partnership between government, academia and industry. We are hopeful that bemcentinib can play a significant role in the global effort to find suitable treatment options for COVID-19 patients, which has had such serious implications for so many people and thereby ease pressures on hospital intensive care units, and ultimately treat thousands of patients. We are poised to commence dosing in the coming days and will provide results as soon as is practically possible.”
Read the press release from BerGenBio
In the Norwegian news: